In July 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …

Transfusions can be a life-saving treatment of patients with sickle-cell disease (SCD).
However, availability of matched units can be limiting because of distinctive blood group …

Red cell transfusion remains a critical component of care for acute and chronic
complications of sickle cell disease. Randomized clinical trials demonstrated the benefits of …

A hemolytic transfusion reaction (HTR) is the accelerated clearance or destruction of red
blood cells associated with a transfusion event. Causes of HTRs and differential diagnoses …

Delayed hemolytic transfusion reaction (DHTR) is a life‐threatening complication of
transfusion in sickle cell disease (SCD). The frequency of DHTR is underestimated because …

Red blood cell (RBC) transfusions can result in alloimmunization toward RBC alloantigens
that can increase the probability of complications following subsequent transfusion. An …

Red blood cells (RBC) transfusion is critical in managing acute and chronic complications in
sickle cell disease (SCD); however, it is complicated by RBC alloimmunization, iron …

Patients with sickle cell disease (SCD) often receive red blood cell (RBC) transfusion
support for the prevention and management of many acute and chronic disease …

Erythrocyte alloimmunization is a major barrier to transfusion in sickle cell disease (SCD)
because it can lead to transfusion deadlock and the development of life-threatening …

Transfusion of red blood cells (RBC) remains a primary treatment modality in patients with
sickle cell disease (SCD). Repeated exposure to alloantigens on transfused RBCs can lead …